ReviewDermatology and therapy2025

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.

Jonathan I Silverberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.